AB0656 SUSTAINED REMISSION IN RHEUMATOID ARTHRITIS: WHAT ARE THE PREDICTIVE FACTORS?

Background:

Rheumatoid arthritis is the most common chronic inflammatory rheumatic disease. Its management is well codified, with the aim of achieving remission according to the TREAT 2 TARGET strategy. However, few data are available on the predictors of prolonged remission.

Objectives:

The aim of this study was to determine the prevalence and predictors of sustained remission in rheumatoid arthritis.

Methods:

This is a retrospective descriptive and analytical study including a sample of 139 patients followed up for rheumatoid arthritis in the rheumatology consultation of the Hassan II University Hospital in Fez. Sustained remission was defined by a disease activity score (DAS28-CRP) below 2.6 over a period of at least six months without recourse to corticosteroids. Predictive factors for sustained remission were identified by logistic regression analysis using SPSS software.

Results:

Of the 139 patients included in our study, the mean age was 59.88 ±13.09 years. Female to male ratio (F/M) was 4/1. 18.7% of our patients were suffering from hypertension, and 19.4% from diabetes. Regarding the characteristics of RA, it was seropositive in 78.1% (107) of patients and erosive in 89.3% (108). 92.1% were on methotrexate, 27.3% (38) on bDMARD. Sustained remission was observed in 40.3% (56) of cases. In linear regression analysis, variables associated with sustained remission were age less than 50 years with p=0.014 and OR= 3.479 (1.663-5.266) 95% CI, HAQ <0.5 with p=0.043 and OR=1.857 (1.090-2.414) 95% CI, seropositive RA with p=0.039 OR = 1.256 (1.070-2.532) 95% CI. The use of Rituximab and TNF alpha(tumor necrosis factor) alpha inhibitors was also associated with sustained remission with p and OR values respectively at p=0.048 OR 4.765 (1.023-7.241) 95% CI and p=0.018 OR 4.295 (1.491-9.547) 95% CI.

Conclusion:

In our sample, and given the results, long term remission was achieved in 40.3% of patients. The following elements were associated with sustained remission: Age under 50, HAQ<0.5, seropositive RA, patients on Rituximab and patients on TNF alpha inhibitors.

REFERENCES:

NIL.

Acknowledgements:

NIL.

Disclosure of Interests:

None declared.